These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 27200543)

  • 1. Understanding the Payer Dilemma with Biosimilar Mabs: Striking the Right Balance Between Budget Needs and Patient Outcomes.
    Vidal Pinheiro A; Ziai Buetas A; Storer M
    Value Health; 2014 Nov; 17(7):A326. PubMed ID: 27200543
    [No Abstract]   [Full Text] [Related]  

  • 2. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of care in single-payer and multipayer health systems.
    Feldman R
    J Health Polit Policy Law; 2009 Aug; 34(4):649-70. PubMed ID: 19633227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of Introducing Biosimilar Infliximab for the Treatment of Auto Immune Disorders In Five European Countries.
    Jha A; Upton A; Dunlop W
    Value Health; 2014 Nov; 17(7):A525. PubMed ID: 27201655
    [No Abstract]   [Full Text] [Related]  

  • 8. Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries.
    Brodszky V; Gulacsi L; Balogh O; Baji P; Rencz F; Péntek M
    Value Health; 2014 Nov; 17(7):A364. PubMed ID: 27200752
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.
    Salesi N; Di Cocco B; Colonna M; Veltri E
    Future Oncol; 2012 May; 8(5):625-30. PubMed ID: 22401144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.
    Beck A; Sanglier-Cianférani S; Van Dorsselaer A
    Anal Chem; 2012 Jun; 84(11):4637-46. PubMed ID: 22510259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development.
    Offman E; Edginton AN
    Xenobiotica; 2013 Jun; 43(6):561-9. PubMed ID: 23244626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory guideline for biosimilar products in Korea.
    Suh SK; Park Y
    Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
    Araújo F; Cordeiro I; Teixeira F; Gonçalves J; Fonseca JE
    Acta Reumatol Port; 2014; 39(1):19-26. PubMed ID: 24811458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.